Jefferies analyst Dennis Ding downgraded Corcept Therapeutics to Hold from Buy with a price target of $22, down from $35.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CORT:
- Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results, Provide Corporate Update and Host Conference Call
- Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation
- Corcept Therapeutics to pay $14M in settlement of class action litigation